Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant

Immunotherapy with toll like receptor 9 (TLR9) agonist CpG ODN offers an emergent strategy to treat life‐threatening malignant glioma. CpG is typically applied invasively by intracranial and intrathecal administration which induces not only poor compliance and lessened potency but also possibly stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jingjing, Wu, Di, Zhao, Songsong, Shao, Yu, Xia, Yifeng, Ni, Dawei, Qiu, Xinyun, Zhang, Jinping, Chen, Jian, Meng, Fenghua, Zhong, Zhiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069387/
https://www.ncbi.nlm.nih.gov/pubmed/35253404
http://dx.doi.org/10.1002/advs.202103689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069387/
https://www.ncbi.nlm.nih.gov/pubmed/35253404
http://dx.doi.org/10.1002/advs.202103689

Ejemplares similares